Lyra Therapeutics Adds Vineeta Belanger, Ph.D., as Senior Vice President of Clinical Affairs
(WorldNews Business)

WATERTOWN, Mass.--(BUSINESS WIRE)--Sep 17, 2019-- Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines designed to precisely target ear, nose and throat (ENT) diseases, today announced that Vineeta Belanger, Ph.D., will join as the company´s Senior Vice President of Clinical Affairs. She brings twenty years of clinical experience in the biotechnology industry. Dr. Belanger joins Lyra at a pivotal time, as the company´s lead drug candidate, LYR-210, progresses through a Phase 2 clinical trial for the treatment of chronic rhinosinusitis (CRS). This press release features multimedia. View the full release here:...